Evidence map›Paper›PMID 33479597›Full record

ArticleFrontiers in oncology2020

NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer.

Yuehong Cui, Qian Li, Wei Li, Yan Wang, Fang Lv, Xinying Shi, Zhaoqing Tang, Zhenbin Shen, Yingyong Hou, Henghui Zhang and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
6.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 78 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Yuehong CuiDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Qian LiDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Wei LiDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yan WangDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Fang LvMedical Department, Beijing Genecast Biotechnology Co., Beijing, China.
Xinying ShiMedical Department, Beijing Genecast Biotechnology Co., Beijing, China.
Zhaoqing TangDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhenbin ShenDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yingyong HouDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Henghui ZhangCenter of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Beibei MaoMedical Department, Beijing Genecast Biotechnology Co., Beijing, China.
Tianshu LiuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
The First Affiliated Hospital, Sun Yat-sen University · CNGenecast (China) · CNSun Yat-sen University · CNCapital Medical University · CNZhongshan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlthough traditional treatments confer survival benefits to patients with gastric cancer (GC), many patients experience relapse soon after postoperative adjuvant therapy. Immune-related mechanisms play an important role in GC, and immunotherapeutic strategies are considered to be a promising direction for the treatment of GC. Thus, our study aimed to investigate the expression and prognostic significance of immune-related genes in GC.

methodsFormalin-fixed, paraffin-embedded samples were collected from 48 resectable GC patients. The transcriptome data of the tumor immune microenvironment were assessed using an immuno-oncology 395-gene panel RNA sequencing platform. The prognostic value of the 395 genes was analyzed and validated in the KM plotter and GEPIA databases. The data from The Cancer Genome Atlas (TCGA, downloaded from UCSC Xena repository) and Tumor IMmune Estimation Resource (TIMER) were used to evaluate the correlations between prognostic factors and immune signatures.

resultsAmong the 395 genes, NOTCH3 was identified as a good prognostic factor for GC patients. Its prognostic value was also suggested in both our GC cohort from Zhongshan Hospital and the public databases (KM plotter and GEPIA database). Mechanistically, high NOTCH3 expression correlated with a lower infiltration of activated CD8

conclusionThese findings uncovered a new mechanism by which NOTCH3 participates in the immune tolerance of GC, implying the potential of NOTCH3 as a therapeutic target or predictive marker for GC patients.

Indexed as

biomarkergastric cancerimmune toleranceNOTCH signalingprognosis

Identifiers

PMID33479597
PMCPMC7814877
OpenAlexW3190196828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.